"The UK government is preparing to sign a major pharmaceuticals agreement with Washington that will remove import tariffs on medicines entering the United States and commit Britain to higher spending on NHS drugs. The deal, expected to be announced within days, follows months of tense negotiations with the Trump administration and comes after a wave of warnings and pulled investments from multinational drug makers frustrated with the UK's commercial environment."
"According to industry sources, the agreement will see the government lower the industry rebate rate applied to branded medicines sold to the NHS and raise the threshold used in the NHS's drug-value assessments. Under the quality-adjusted life year (QALY) measure - which evaluates the cost of treatments relative to the healthy years they deliver - the upper limit will increase by around 25 per cent from the current £30,000 per year. The government has also agreed to increase the share of the overall NHS budget"
A UK–US pharmaceuticals agreement will remove US import tariffs on medicines and commit Britain to higher NHS drug spending. The agreement lowers the industry rebate rate for branded medicines sold to the NHS and raises the QALY threshold by about 25% from £30,000 per year. The government will increase the share of the NHS budget allocated to medicines. Negotiations were led by senior UK advisers and targeted US concerns about price gaps, with tariff pressure used as leverage. Pharmaceutical leaders in London and Washington engaged to restore investment confidence after tensions over VPAG and UK rebate levels.
Read at Business Matters
Unable to calculate read time
Collection
[
|
...
]